Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATRANASDAQ:CRTXNASDAQ:KRYSNASDAQ:MGTXNASDAQ:VCEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$0.70+6.1%$0.74$0.20▼$3.08$71.34M0.713.20 million shs1.05 million shsCRTXCortexyme$1.13$1.26$1.78▼$40.66$34.07M1.4620,672 shs60,549 shsKRYSKrystal Biotech$177.20+1.7%$140.68$77.10▼$189.97$4.93B0.86463,833 shs349,192 shsMGTXMeiraGTx$6.21+0.8%$6.25$3.49▼$8.35$395.58M1.3151,537 shs140,061 shsVCELVericel$52.33+5.6%$45.47$28.02▼$52.43$2.53B1.69603,938 shs576,564 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+5.90%-2.78%-1.55%+27.62%-75.52%CRTXCortexyme0.00%-6.61%-15.04%+0.89%-23.65%KRYSKrystal Biotech+1.74%+3.43%+12.87%+38.70%+123.79%MGTXMeiraGTx+0.81%-4.31%+6.34%-12.78%+23.21%VCELVericel+5.59%+14.38%+8.84%+45.28%+85.83%Trending Stocks Sent To You In Real Time (Ad)Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next AlertMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics4.1568 of 5 stars3.02.00.04.72.02.51.3CRTXCortexymeN/AN/AN/AN/AN/AN/AN/AN/AKRYSKrystal Biotech3.8623 of 5 stars1.53.00.04.72.03.31.9MGTXMeiraGTx4.6043 of 5 stars3.54.00.04.83.31.70.6VCELVericel0.6543 of 5 stars1.52.00.00.02.00.81.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics2.00Hold$28.003,900.00% UpsideCRTXCortexymeN/AN/AN/AN/AKRYSKrystal Biotech3.00Buy$157.67-11.02% DownsideMGTXMeiraGTx3.00Buy$25.67313.31% UpsideVCELVericel3.00Buy$46.40-11.33% DownsideCurrent Analyst RatingsLatest ATRA, KRYS, MGTX, CRTX, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.003/1/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$51.00 ➝ $54.003/1/2024VCELVericelHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$46.00 ➝ $53.002/27/2024KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $175.002/27/2024KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$160.00 ➝ $195.002/27/2024KRYSKrystal BiotechWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform1/25/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$39.00 ➝ $51.001/16/2024VCELVericelHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$44.50 ➝ $46.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$63.57M1.12N/AN/A$1.33 per share0.53CRTXCortexymeN/AN/AN/AN/A$3.97 per shareN/AKRYSKrystal Biotech$50.70M98.88N/AN/A$27.60 per share6.42MGTXMeiraGTx$14.02M28.45N/AN/A$2.17 per share2.86VCELVericel$197.52M12.82$0.02 per share2,720.47$4.73 per share11.06Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$228.30M-$2.78N/AN/AN/A-6,390.31%-783.31%-104.24%N/ACRTXCortexyme-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/AKRYSKrystal Biotech$10.93M$0.082,215.2848.02N/AN/A-13.31%-12.61%5/13/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A6.90N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)VCELVericel-$3.18M-$0.09N/A111.34N/A-1.61%-1.55%-1.02%5/8/2024 (Estimated)Latest ATRA, KRYS, MGTX, CRTX, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023VCELVericel$0.18$0.26+$0.08$0.26$64.28 million$65.00 million 2/26/202412/31/2023KRYSKrystal Biotech-$0.52$0.30+$0.82$0.30$27.43 million$42.14 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACRTXCortexymeN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A1.501.42CRTXCortexymeN/A9.929.92KRYSKrystal BiotechN/A17.7617.55MGTXMeiraGTx0.622.382.38VCELVericelN/A4.494.21OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%CRTXCortexyme63.18%KRYSKrystal Biotech86.29%MGTXMeiraGTx67.48%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.50%CRTXCortexyme27.90%KRYSKrystal Biotech17.00%MGTXMeiraGTx9.70%VCELVericel6.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics334101.92 million97.34 millionOptionableCRTXCortexyme5530.15 million21.74 millionNot OptionableKRYSKrystal Biotech22928.29 million23.48 millionOptionableMGTXMeiraGTx41964.22 million57.99 millionOptionableVCELVericel31448.38 million45.28 millionOptionableATRA, KRYS, MGTX, CRTX, and VCEL HeadlinesSourceHeadlineVericel (NASDAQ:VCEL) Sets New 1-Year High at $51.40marketbeat.com - March 27 at 11:23 AMVericel's (VCEL) "Buy" Rating Reaffirmed at Truist Financialamericanbankingnews.com - March 27 at 3:32 AMAnalyst Scoreboard: 5 Ratings For Vericelmarkets.businessinsider.com - March 27 at 1:54 AMTruist Financial Reaffirms "Buy" Rating for Vericel (NASDAQ:VCEL)marketbeat.com - March 26 at 9:35 AMVericel (NASDAQ:VCEL) and Twist Bioscience (NASDAQ:TWST) Head-To-Head Contrastamericanbankingnews.com - March 21 at 5:22 AMVericel Co. (NASDAQ:VCEL) Shares Sold by Public Sector Pension Investment Boardmarketbeat.com - March 20 at 4:17 AMDominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) Stockinsidertrades.com - March 17 at 5:42 AMWalleye Capital LLC Acquires New Holdings in Vericel Co. (NASDAQ:VCEL)marketbeat.com - March 17 at 4:20 AMVericel Co. (NASDAQ:VCEL) CEO Sells $781,725.00 in Stockmarketbeat.com - March 15 at 4:46 PMShort Interest in Vericel Co. (NASDAQ:VCEL) Increases By 18.8%marketbeat.com - March 15 at 3:33 PMVericel Co. (NASDAQ:VCEL) COO Sells $352,046.54 in Stockinsidertrades.com - March 14 at 9:39 AMVericel Co. (NASDAQ:VCEL) SVP Sells $367,852.95 in Stockinsidertrades.com - March 12 at 4:46 AMEnvestnet Asset Management Inc. Raises Stock Position in Vericel Co. (NASDAQ:VCEL)marketbeat.com - March 9 at 4:13 AMBaker Avenue Asset Management LP Takes $1.30 Million Position in Vericel Co. (NASDAQ:VCEL)marketbeat.com - March 8 at 8:31 AMInvesco Ltd. Cuts Stake in Vericel Co. (NASDAQ:VCEL)marketbeat.com - March 6 at 4:59 AMVericel Co. (NASDAQ:VCEL) Position Increased by Fmr LLCmarketbeat.com - March 5 at 6:27 AMVericel Co. (NASDAQ:VCEL) is Kent Lake Capital LLC's 7th Largest Positionmarketbeat.com - March 4 at 4:29 PMVCEL Oct 2024 50.000 callca.finance.yahoo.com - March 3 at 7:05 PMUS$52.07 - That's What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These Resultsfinance.yahoo.com - March 3 at 9:03 AMVericel Corporation (VCEL) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 2 at 7:12 PMVericel Full Year 2023 Earnings: EPS Beats Expectationsfinance.yahoo.com - March 2 at 8:15 AMVericel (NASDAQ:VCEL) Announces Earnings Results, Beats Estimates By $0.08 EPSmarketbeat.com - March 1 at 2:38 PMBuy Rating Affirmed for Vericel on Strong Financials and Growth Prospectsmarkets.businessinsider.com - March 1 at 12:06 PMA Closer Look at 4 Analyst Recommendations For Vericelmarkets.businessinsider.com - March 1 at 12:06 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAtara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.CortexymeNASDAQ:CRTXCortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Krystal BiotechNASDAQ:KRYSKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.VericelNASDAQ:VCELVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.